Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $118.15M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 9.92M
Average 2.73M
Returns on capital
Inovio Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-352.5%
avg -417.0%
ROIC
-259.4%
avg -93.0%
ROA
-114.3%
avg -65.5%
Analysis
ROA is currently the strongest return metric at -114.3% versus its period average of -65.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jacqueline E. Shea | Chief Executive Officer, President & Director | USD 889.1K | 60 | — | — |
Laurent Humeau | Chief Scientific Officer & Chairman of the Scientific Advisory Board | USD 794.08K | 59 | 12.05K | 0.02% |
Michael Sumner | Chief Medical Officer & Head of Development | USD 653.48K | 61 | — | — |
Peter D. Kies | Chief Financial Officer | USD 598.28K | 63 | — | — |
Shawn D. Bridy | Senior Vice President of Business Development | — | — | — | — |
Jeffrey Skolnik | Senior Vice President of Clinical Development | — | — | — | — |
E. J. Brandreth | Senior Vice President of Quality Assurance | — | — | — | — |
Robert J. Juba Jr. | Senior Vice President of Biological Manufacturing & Clinical Supply Management | — | — | — | — |
Robert L. Crotty | General Counsel, Corporate Secretary & Chief Compliance Officer | — | 52 | — | — |
Jennie Willson | Director of Communications | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 20, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -81.5% | +467.8% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -81.5% over three years. Forward estimates point to Revenue at +467.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Inovio Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about INO's management, answered from reported figures.
Who manages INO?
Inovio Pharmaceuticals, Inc. (INO) lists 10 active executives. The top listed executive is Shawn D. Bridy, Senior Vice President of Business Development.
Are INO insiders buying or selling?
Recent insider activity shows net buying of $1.81M.
Continue the stock analysis
Jump to another research area for this company.